This study looks at how well a drug called Reparixin works when added to regular treatment for people who have pneumonia, including COVID-19. Pneumonia is a lung infection that can make it hard to breathe. The study is double-blind (neither doctors nor patients know who's getting the real drug or a fake one) and randomized (people are randomly picked to get either the drug or placebo). The trial will test 526 patients, and each person will take the medicine for up to 21 days. The main goal is to see if the drug helps stop the illness from getting worse. Safety will also be checked.

• Participation Length: Up to 21 days of treatment.
• Visits/Checks: Regular monitoring up to 180 days.
• Compensation: None mentioned.

To join, you must be 18 or older, already in the hospital for pneumonia, and need extra oxygen. You shouldn't join if you have liver or kidney issues, or other serious health problems. Pregnant women or those who might get pregnant during the study cannot participate. A negative pregnancy test is required before starting.